Literature DB >> 31891571

Molecular characterization of fowl adenovirus isolate of Malaysia attenuated in chicken embryo liver cells and its pathogenicity and immunogenicity in chickens.

Norfitriah Mohamed Sohaimi1, Mohd Hair Bejo1,2, Abdul Rahman Omar1,2, Aini Ideris1,2, Nurulfiza Mat Isa2,3.   

Abstract

Fowl adenovirus (FAdV) is the causative agent of inclusion body hepatitis (IBH) in chickens with significant economic losses due to high mortality and poor production. It was objectives of the study to attenuate and determine the molecular characteristic of FAdV isolate (UPM1137) of Malaysia passages in primary chicken embryo liver (CEL) cells. The cytopathic effect (CPE) was recorded and the present of the virus was detected by polymerase chain reaction (PCR). Nucleotide and amino acid changes were determined and a phylogenetic tree was constructed. The pathogenicity and immunogenicity of the virus at passage 35 (CEL35) with virus titre of 106.7TCID50/mL was determined in day old specific pathogen free (SPF) chicks via oral or subcutaneous route of inoculation. The study demonstrated that the FAdV isolate was successfully propagated and attenuated in CEL cells up to 35th consecutive passages (CEL35) with delayed of CPE formation within 48 to 72 post inoculation (pi) from CEL20 onwards. The virus caused typical CPE with basophilic intranuclear inclusion bodies, refractile and clumping of cells. The virus is belong to serotype 8b with substitution of amino acid at position 44, 133 and 185 in L1 loop of hexon gene and in knob of fiber gene at position 348 and 360 at CEL35. It is non-pathogenic, but immunogenic in SPF chickens. It was concluded that the FAdV isolate was successfully attenuated in CEL cells with molecular changes in major capsid proteins which affect its infectivity in cell culture and SPF chickens.

Entities:  

Mesh:

Year:  2019        PMID: 31891571      PMCID: PMC6938336          DOI: 10.1371/journal.pone.0225863

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Fowl adenovirus (FAdV) is an important causative agent of devastating disease known as inclusion body hepatitis (IBH) in poultry with significant economic impact due to high mortality and poor production [1, 2]. The virus is classified as Aviadenovirus genus under family of Adenoviridae with five molecular species group designated as letter A to E, and 12 serotypes [3]. Highly pathogenic FAdV is the primary pathogen of IBH and hydropericardium syndrome (HPS) due to FAdV-1, FAdV-8, FAdV-9 and FAdV-4 infection, respectively. The infection caused sudden onset of high mortality and immunosuppresion in chickens [2, 4, 5, 6, 7]. In Malaysia, IBH outbreak was first reported by Hair-Bejo in 2005 [8] in commercial broiler chickens with 10% mortality. Since then, the number of IBH and gizzard erosion cases were increased due to FAdV Group E serotype 8b infection [9, 10]. Vaccination is not a common practice in the country and suitable vaccine against the disease is unavailable. A few approaches of viral attenuation such as serial passages in cell culture or chicken embryos were reported previously for the development of live attenuated vaccine [11, 12]. It seems that avian origin cells such as primary chicken embryo liver (CEL) cells are the superior medium for FAdV adaptation as compared to mammalian cells [13, 14]. In addition, continuous cell line from chicken hepatoma cells and QT35 quail fibroblast cells, and mammalian cell line from Vero cells were also used previously [11, 15, 16]. The characterization of major capsid proteins are extensively used in determination of virulence gene in FAdV isolate [5, 17]. Mutation of nucleotide and amino acids at L1 loop region in hexon gene affect virus virulence and resulting attenuation of FAdV following passage in chicken embryonated eggs [10, 12]. However, the marker for adaptation and attenuation of FAdV in CEL cells remained unknown which typically important for localization of specific region encoded for virus infectivity. Previous mutation analysis basically performed solely on hexon gene without involvement of fiber gene which located at outermost part of virus capsid for primary attachment to host cells receptor [12]. Although FAdV routinely isolated in CEL cells, the impact of serial passages in this medium towards molecular changes in hexon and fiber gene specifically at nucleotide and amino acid level which may affect viral infectivity in the host are poorly known. It was objectives of the study to propagate and attenuate FAdV isolate (UPM1137) in primary CEL cells. The molecular characteristic of the virus at various passages was determined. The pathogenicity and immunogenicity of the virus isolate at passage 35 (CEL35) was determined in the specific pathogen free (SPF) chickens.

Materials and methods

Virus

FAdV isolate, UPM1137, was obtained from an outbreak of IBH and gizzard erosion in 27 weeks old commercial layer chickens with 2% mortality. Upon necropsy, the liver was pale and friable with erosion in koilin layer of gizzard. Both liver and gizzard samples were positive for FAdV by histological examination and conventional polymerase chain reaction (PCR) [18]. Liver from the infected chickens was collected and processed by three times frozen and thawed prior macerated with a sterile mortar and pestle for preparation 1 in 2 (w/v) suspension in sterile phosphate buffered saline (PBS, pH 7.4, 0.1M). For clarification, suspension was centrifuged at 381 x g for 30 minutes and the supernatant was collected and purified by filtration through 0.45μm syringe filter. Liver homogenates was treated with commercial antibiotic-antimycotic solution (GIBCO Laboratories, New York, NY, USA) at 1 in 10 (v/v) dilutions and incubated at 4°C for 1 hour prior inoculation [19]. The virus inoculum (0.1 mL) was then inoculated in SPF embryonated chicken eggs via chorioallantoic membrane (CAM) route. The eggs were candled daily for mortality. Severe hepatic necrosis was recorded in the dead embryos. The liver was harvested for the next passage (E2) in SPF eggs for the preparation of inoculum used in the present study. DOI: dx.doi.org/10.17504/protocols.io.7zjhp4n.

Preparation of primary chicken embryo liver (CEL) cells

Primary CEL cell was obtained from liver embryos of 13 to 15 days old SPF embryonated chicken eggs. Liver was harvested aseptically using sterile forceps and washed twice with sterile phosphate buffered saline (PBS, pH 7.4, 0.1M). The liver tissue was minced and trypsinized gently with 0.25% Trypsin-EDTA solution for 10 minutes. The suspension was passed through muslin cloth and centrifuged at 96 x g for 5 minutes to obtain cell pellet. Trypsin was discarded and cell pellet was resuspended with fresh Dulbecco`s Modification Eagle Medium (DMEM), enriched with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin antibiotic. Cell concentration was counted and adjusted to 5 x106 cells/mL. The cell suspension (5mL) was seeded into new 25cm2 cell culture flasks and was kept under controlled atmosphere at 5% CO2 incubator with 85%-90% humidity until confluent monolayer formed [14]. DOI: dx.doi.org/10.17504/protocols.io.7zchp2w.

Propagation and attenuation of FAdV isolate in CEL cells

A confluent monolayer was washed twice with serum free medium and inoculated with 0.1mL of homogenate liver embryos and labeled as first passage (CEL1). Infected flasks were incubated at 37°C for 60 minutes for virus adsorption and added with maintenance medium containing 2% fetal bovine serum (FBS) under 37°C incubator. The cells were observed daily under inverted microscope for cytopathic effect (CPE) for 3 days post-inoculation (pi). Flasks with prominent CPE were harvested by 3 times repeated frozen and thawed prior centrifugation at 216 x g for 10 minutes. Virus supernatant was collected and stored at -20°C prior inoculation for subsequence passages. Fresh confluent monolayer was prepared for each passage and inoculated with 0.1mL of viral supernatant and continued until 35th consecutive passage. For non-infected flasks, monolayer remained uninoculated and was used as control cells. DOI: dx.doi.org/10.17504/protocols.io.7zdhp26.

Haematoxylin and eosin staining

For detection of intranuclear inclusion bodies, primary CEL cells were grown on sterile coverslips [20]. Briefly, the growth medium was aspirated out from confluent monolayer and washed twice with sterile medium free serum prior to inoculation of 0.1mL viral supernatant. Culture was added with maintenance medium, DMEM and 2% FBS and kept for 48 hours incubation, harvested and fixed in 10% buffered formalin for 5 minutes and stained with haematoxylin and eosin (HE). DOI: dx.doi.org/10.17504/protocols.io.7zghp3w.

Virus titration

Viral supernatant from passage 5 (CEL5), CEL10, CEL15, CEL20, CEL25, CEL30 and CEL35 were determined for titration by 50% tissue culture infective dose (TCID50) as described by Reed and Muench [21]. Supernatant was diluted for 10 folds serial dilution and inoculated onto fresh CEL cells in 96 wells plate and monitored daily for CPE. Virus titre was calculated and expressed as TCID50/mL. DOI: dx.doi.org/10.17504/protocols.io.7zhhp36.

DNA extraction and quantitation

DNA was extracted from 200μl of homogenate liver embryos (E2) and viral supernatant from propagated isolates in primary CEL cells from CEL1, CEL5, CEL10, CEL15, CEL20, CEL25, CEL30 and CEL35 using i-Genomic DNA Extraction Mini kit (iNtRON Biotechnology, Inc., Korea). The protocol was followed according to manufacture recommendations using spin column method. Extracted DNA was measured for DNA concentration by biophotometer (Eppendorf) at wavelength 260/280nm.

PCR and cloning

Amplification of DNA was performed by two set of published hexon gene primers, H1/H2 and H3/H4 [22] and fiber gene primer, FibF/FibR, FibF: 5`-GGTCTACCCCTTTTGGCTCC-3`and FibR: 5`-GCGTCGTAGATGAAGGGAGG-3`[10] according to manufacture protocol (Bioline, UK). The PCR products were analyzed by electrophoresis in a 1% agarose gel stained with RedSafe™ Nuclei Acid Staining solution (iNtRON, Korea) at 70 volts for 45 minutes and visualized under U.V. transillumination. Purification of PCR products were carried out by using MEGAquick-spin™ Total Fragment DNA Purification kit (iNtRON) based on the manufacture recommendation. Purified PCR products from H1/H2 and FibF/FibR were cloned into the pCR™ 2.1-TOPO® vector using TOPO TA Cloning kit (Invitrogen, USA). Positive cloned was analyzed by colony-PCR prior plasmid extraction using DNA-spin™ Plasmid DNA Purification kit (iNtRON) and stored at -20°C until used. DOI: dx.doi.org/10.17504/protocols.io.7zfhp3n.

Sequencing and sequence analysis

Plasmid from original isolate and series of propagated isolates were subjected to DNA sequencing on an automatic sequencer, ABI PRISM 3730xl Genetic Analyzer (Applied Biosystems, USA) using the BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, USA). Sequencing was conducted at least three times to obtain consensus sequences using universal primers, T7 promoter and M13R_pUC26 for both direction [10]. The sequence was verified as fowl adenovirus Group E based on NCBI BLAST GenBank. Nucleotide sequences were assembled, edited and analyzed using BioEdit Version 7.2.5. Sequence was translated into amino acid sequences using online ExPASy tool program. Multiple sequence alignment was carried out using ClustalW program in BioEdit version 7.2.5 package to compare nucleotide and deduced amino acids sequence between original isolate (E2) and propagated isolates in CEL cells. The E2 FAdV designated as UPM1137E2 with GenBank accession number KF866370 (hexon) and KY305950 (fiber). Sequence difference count matrix was carried out to calculate nucleotide and amino acid changes between each passage before and after attenuation. In addition, location for variable L1 loop hexon gene and knob region in fiber gene was identified by alignment with reference FAdV gene, HG strain [23]. L1 loop of hexon gene corresponding to residue 101 to 298 of HG strain, while for fiber gene as follows: Tail: 1–75, Shaft: 76–356, Knob: 369–523 [17]. DOI: dx.doi.org/10.17504/protocols.io.7zehp3e.

Phylogenetic analysis

Twenty-eight published FAdVs hexon (Table 1) and fiber (Table 2) gene sequences were obtained from GenBank. Another two reference strains from different genus avian adenovirus was used which are Duck adenovirus (Atadenovirus) and Turkey adenovirus (Siadenovirus). Multiple sequence alignment of nucleotide and deduced amino acid were conducted using BioEdit Version 7.2.5 and Mega Version 5 software. A region of L1 loop in hexon gene with 198 amino acids and entire region of fiber gene was selected for construction of phylogenetic tree. Jones-Taylor-Thorton (JTT) model was used to compute distance matrix using MEGA software and followed by phylogenetic tree construction using Neighbour-joining method with 1000 boostrap replicates [9]. DOI: dx.doi.org/10.17504/protocols.io.7zihp4e.
Table 1

Thirty avian adenovirus strains for hexon gene nucleotide and amino acids were used in the phylogenetic tree analysis.

No.StrainsAccession numberGroupaReferences
NucleotideAmino acid
1CELOZ67970CAA91908AS1 File [A]
2PL/060/08GU952110ADF57268AS1 File [B]
3340AF508952AAN77078BS1 File [C]
4TR22AF508953AAN77079BS1 File [D]
5KR5AF508951AAN77077CS1 File [E]
6B1-7KU342001ANG08820CS1 File [F]
7J2-AAF339917AAL13220CS1 File [G]
8C2BEU979377ACL68145CS1 File [H]
9SR48AF508946AAN77072DS1 File [I]
10P7-AAF339915AAL13218DS1 File [J]
11SR49AF508948AAN77074DS1 File [K]
1275AF508949AAN77075DS1 File [L]
13A-2ANC_000899NP_050287DS1 File [M]
14380KT862812ANJ02603DS1 File [N]
151047DQ323984ABD83863DS1 File [O]
16UF71EU979378ACL68146DS1 File [P]
17CR119AF508954AAN77080ES1 File [Q]
18YR36AF508955AAN77081ES1 File [R]
19B-3AAF339922AAL13225ES1 File [S]
2058AF508957AAN77083ES1 File [T]
21TR59EU979374ACL68142ES1 File [U]
22764JN112373AER40292ES1 File [V]
23Australian FAdV vaccineGU120268ADD49658ES1 File [W]
24430–06GU120266ADD49656ES1 File [X]
25HGGU734104ADE58399ES1 File [Y]
26UPM08158JF917238AEL21619ES1 File [Z]
27UPM08136JF917239AEL21620ES1 File [AA]
28UPM04217KU517714ANA50319ES1 File [BB]
29Duck adenovirusKF286430AGS11274N/AS1 File [CC]
30Turkey adenovirusAC_000016AP_000486N/AS1 File [DD]

N/A = not applicable

FAdV comprised of 5 molecular groups designated as letter A, B, C, D and E.

Table 2

Thirty avian adenovirus strains for fiber gene nucleotide and amino acids were used in the phylogenetic tree analysis.

No.StrainsAccession numberGroupaReferences
NucleotideAmino acid
1CELOU46933AAC54918AS1 File [EE]
2OTEFN557186CBH20110AS1 File [FF]
3PL/060/08GU952108ADF57266AS1 File [GG]
408–3622FN557184CBH20108AS1 File [HH]
5340FR872928CCB84856BS1 File [II]
6B1-7KU342001ANG08832CS1 File [F]
7BareillyFJ949088ACR54094CS1 File [JJ]
8Kr-YeojuHQ709232ADV35562CS1 File [KK]
9Kr-GunwiHQ709231ADV35561CS1 File [LL]
10AG234HE608153CCE39400CS1 File [MM]
11INT4FR872911CCB84839CS1 File [NN]
12ON1GU188428ADQ39072CS1 File [OO]
13C2BHE608154CCE39405CS1 File [PP]
14SR48LN907576CUT98205DS1 File [QQ]
15685KT862805ANJ02352DS1 File [RR]
16SR49LN907578CUT98207DS1 File [SS]
17A-2ANC_000899NP_050293DS1 File [M]
18380LN907574CUT98203DS1 File [TT]
1905-50052-2924-1JQ034217AFD32284DS1 File [UU]
2005-50052-3181JQ034218AFD32285DS1 File [VV]
21CR119LN907584CUT98213ES1 File [WW]
22YR36LN907582CUT98211ES1 File [XX]
23TR59KT037703ANQ43480ES1 File [YY]
24764KT037711ANQ43488ES1 File [ZZ]
25HGGU734104ADE58406ES1 File [Y]
26CFA3FAU40588AAC55302ES1 File [AAA]
27CFA40AF155911AAF17339ES1 File [BBB]
28UPM04217KU517714ANA50324ES1 File [BB]
29Duck adenovirusKF286430AGS11279N/AS1 File [CC]
30Turkey adenovirusAC_000016AP_000495N/AS1 File [DD]

N/A = not applicable

FAdV comprised of 5 molecular groups designated as letter A, B, C, D and E

N/A = not applicable FAdV comprised of 5 molecular groups designated as letter A, B, C, D and E. N/A = not applicable FAdV comprised of 5 molecular groups designated as letter A, B, C, D and E

Pathogenicity and immunogenicity of the FAdV CEL35 isolate in SPF chickens

Twenty eight day-old SPF White Leghorn layer chickens were divided into three groups, namely groups A, B and C. Eight chickens each were assigned in groups A and B separately and twelve chickens in group C. All chickens in groups A and B were inoculated with 0.1mL FAdV isolate, UPM1137CEL35 with virus titre of 106.7TCID50/mL via oral and subcutaneous route, respectively at day old of age. Twelve chickens in group C remained uninoculated throughout the trial and acted as the control group. All chickens were monitored daily throughout 28 days post-inoculation (pi). Feed and water were given ad-libitum. Four chickens were sacrificed by cervical dislocation at day 0pi in group C followed by days 14 and 28pi in all groups. The body weight and blood were collected prior to sacrifice. On necropsy, the gross lesions were recorded and samples of trachea, liver and gizzard were collected and fixed in 10% buffered formalin for histological examination. The FAdV antibody titre was determined by enzyme linked immunoabsorbent assay (ELISA) test using commercial kit (BioChek, UK, Ltd.) based on manufacture`s recommendation. The animal study was conducted under approval of Institutional Animal Care and Use Committee (IACUC), Universiti Putra Malaysia with AUP No. R076/2015. DOI: dx.doi.org/10.17504/protocols.io.8ydhxs6.

Statistical analysis

Mean body weight and antibody titre were analyzed by analysis of variance (ANOVA) using SPSS version 22 with significant value p<0.05. The significant data was determined further by Tukey honest significant difference test. Independent T-test was performed to compare between two group means.

Results

Cytopathic effects (CPEs)

The uninfected primary CEL cells showed large irregular epithelial island of cells comprising of hepatocytes and surrounded by network of fibroblasts (Fig 1(A)). At first passage after inoculated with FAdV isolate, CPE was not observed until day 3 pi. From second to 35th passages, CPE was detected majority in epithelial islands in the form of refractile, rounding, clumping and detachment of cells from the monolayer of the flasks. Fibroblasts were largely unaffected and remained normal throughout the trial. Early CPE was recorded started from second to 19th passage onwards within 24 to 48 hours pi. The complete CPE was detected at earliest period at 26 hours pi from CEL2 to CEL8 (Fig 1(B)) followed by 32 hours pi at CEL9 to CEL13 (Fig 1(C)). From CEL14 to CEL19, complete CPE was recorded at 42 hours pi. However, CPE formation was delayed from CEL20 to CEL35 within 48 to 72 hours pi. Beginning at CEL20 to CEL22, CPE was completed at 52 hours pi (Fig 1(D)). The period gradually increased at CEL23 to CEL27 at 56 hours pi followed by CEL28 to CEL32 at 62 hours pi (Fig 1(E)). The slowest complete CPE was recorded from CEL33 to CEL35 at 70 hours pi (Fig 1(F)).
Fig 1

Cytopathic effects of chicken embryo liver (CEL) cells following inoculation with FAdV isolate, UPM1137.

(a) Uninfected primary CEL cells with large irregular epithelial islands (thick arrow) surrounded by network of fibroblast (line arrows) after 4 days culture. (b) Passage 2 (CEL2) infected cells with refractile, rounding and clumping of cells (arrows) at 26 hours pi. (c) Passage 10 (CEL10) infected cells with refractile, rounded and clumping of cells (arrows) at 32 hours pi. (d) Passage 20 (CEL20) infected cells with clumping of (arrows) at 52 hours pi. (e) Passage 30 (CEL30) infected cells with clumping of cells at 62 hours pi. (f) Passage 35 (CEL35) infected cells with refractile, rounding and clumping of cells on entire monolayer (arrows) at 70 hours pi, Scale bar = 100μm.

Cytopathic effects of chicken embryo liver (CEL) cells following inoculation with FAdV isolate, UPM1137.

(a) Uninfected primary CEL cells with large irregular epithelial islands (thick arrow) surrounded by network of fibroblast (line arrows) after 4 days culture. (b) Passage 2 (CEL2) infected cells with refractile, rounding and clumping of cells (arrows) at 26 hours pi. (c) Passage 10 (CEL10) infected cells with refractile, rounded and clumping of cells (arrows) at 32 hours pi. (d) Passage 20 (CEL20) infected cells with clumping of (arrows) at 52 hours pi. (e) Passage 30 (CEL30) infected cells with clumping of cells at 62 hours pi. (f) Passage 35 (CEL35) infected cells with refractile, rounding and clumping of cells on entire monolayer (arrows) at 70 hours pi, Scale bar = 100μm. In early stage of infection, cells were rounded and refractile at 12 hours pi. At 12 hours later (24 hours pi), infected cells were aggregated and form clumping of cells. At late stage of infection, complete CPE (>80%) was recorded within 24 to 48 hours pi with detachment of cells from monolayer flasks. As compared to passage 20 (CEL20) onwards, infected cells begun to refractile and rounded at 24 hours pi and form clumping on 12 hours later (36 hours pi). Detachment of cells with complete CPE was observed within 48 to 72 hours pi. Non-infected cultures remained normal throughout study period. The uninfected cells were remained normal throughout the trial (Fig 2(A)). Numerous basophilic intranuclear inclusion bodies were observed in the infected cells at 48 hours pi (CEL35) (Fig 2(B)).
Fig 2

Chicken embryo liver (CEL) cells stained with haematoxylin and eosin for detection of basophilic intranuclear inclusion bodies.

(a) Normal CEL cells comprising epithelial island of hepatocytes (thick arrow) surrounded by fibroblasts (thin arrow) at 48 hours post cultured. (b) Infected CEL cells by FAdV isolate (CEL35) at 48 hours pi with CPE of cells detachment and presence of basophilic intranuclear inclusion bodies (thick arrow) surrounded by unaffected fibroblast, Scale bar = 50.0μm.

Chicken embryo liver (CEL) cells stained with haematoxylin and eosin for detection of basophilic intranuclear inclusion bodies.

(a) Normal CEL cells comprising epithelial island of hepatocytes (thick arrow) surrounded by fibroblasts (thin arrow) at 48 hours post cultured. (b) Infected CEL cells by FAdV isolate (CEL35) at 48 hours pi with CPE of cells detachment and presence of basophilic intranuclear inclusion bodies (thick arrow) surrounded by unaffected fibroblast, Scale bar = 50.0μm.

Virus titration of propagated isolates

The virus titre was highest at passage 5 (CEL5) with 107.6TCID50/mL. For subsequence passages at CEL10 to CEL30, the titre ranging from 106.2TCID50/mL to 106.8TCID50/mL. The virus titre was 106.7TCID50/mL at passage 35 (CEL35).

Molecular detection by PCR

The original isolate (E2) and CEL cells propagated isolates from the first passage (CEL1) to 35th passages (CEL35) were positive for FAdV with amplified PCR fragment size of 1219bp, 1319bp and 1124bp using H1/H2, H3/H4 and FibF/FibR primers, respectively (Fig 3(A), 3(B) and 3(C)).
Fig 3

Electrophoresis of polymerase chain reaction products amplifying hexon and fiber gene regions of FAdV using primers, H1/H2, H3/H4 and FibF/FibR with fragment sizes of (a): 1219bp, (b): 1319bp, and (c): 1124bp in 1% agarose gel from sample of the original passage (E2) and passaged FAdV isolates in chicken embryo liver cells. Lane M: 1kb DNA Marker (iNtRON), Lane 1: Positive control (UPM04217), Lane 2: Original isolate (E2), Lane 3: CEL1 FAdV, Lane 4: CEL5 FAdV, Lane 5: CEL10 FAdV, Lane 6: CEL15 FAdV, Lane 7: CEL20 FAdV, Lane 8: CEL25 FAdV, Lane 9: CEL30 FAdV, Lane 10: CEL35 FAdV, Lane 11: Negative control.

Electrophoresis of polymerase chain reaction products amplifying hexon and fiber gene regions of FAdV using primers, H1/H2, H3/H4 and FibF/FibR with fragment sizes of (a): 1219bp, (b): 1319bp, and (c): 1124bp in 1% agarose gel from sample of the original passage (E2) and passaged FAdV isolates in chicken embryo liver cells. Lane M: 1kb DNA Marker (iNtRON), Lane 1: Positive control (UPM04217), Lane 2: Original isolate (E2), Lane 3: CEL1 FAdV, Lane 4: CEL5 FAdV, Lane 5: CEL10 FAdV, Lane 6: CEL15 FAdV, Lane 7: CEL20 FAdV, Lane 8: CEL25 FAdV, Lane 9: CEL30 FAdV, Lane 10: CEL35 FAdV, Lane 11: Negative control.

Nucleotide, amino acids sequences and phylogenetic tree analysis

Analysis of partial hexon and fiber gene nucleotides in FAdV isolate from E2 or namely as UPM1137E2 was confirmed that the isolate belong to FAdV species E and showing 97% to 99% identity with the UPM04217 and 764 strains. The nucleotide of hexon and fiber genes with 1166bp and 1094bp length, respectively, in FAdV isolate throughout 35th consecutive passages at CEL5, CEL10, CEL15, CEL20, CEL25, CEL30 and CEL35 belong to similar species and showing 99% identity with UPM1137E2 following propagation in CEL cells. Several nucleotide (nt) and amino acid (aa) changes were detected in FAdV isolate following 35th consecutive passages in CEL cells. The hypervariable region in hexon gene, L1 loop, was determined to locate the changes specifically in every five consecutive passages and was identified at position 6 to 601 in nucleotides sequence and at position 2 to 199 in amino acid sequence. There are 1nt base substitution at position 90(T-C) within L1 loop at CEL5 to CEL35 compared to E2 isolate before adaptation in CEL cells. Additional one nt change was detected in CEL5 (GenBank: KY305943), CEL10 (GenBank: KY305944) and CEL15 (GenBank: KY305945) at three different positions in each passage at 107(C-T), 1128(G-C) and 732(A-G), respectively. Those nt changes in CEL10 and CEL15 resulting alteration in deduced amino acid at position 376(A-P) and 244(M-V), respectively. For subsequence passage, there are additional 2nt bases changes in CEL20 (GenBank: KY305946) at position 227(C-T) and 1080(A-G) resulting 1aa substitution at position 360(I-V). Major hexon gene changes were detected at CEL25 (GenBank: KY305947) involving other 4nt bases at position 142(A-G), 292(C-T), 368(A-G) and 1122(A-C) along with 3aa in deduced amino acid at position 47(N-S), 97(P-L) and 374(T-P). Propagation of UPM1137 isolate at passage 30 (CEL30) (GenBank: KY305948) in CEL cells resulting 2nt bases substitution at position 90(T-C) and 274(A-G) with changing in deduced amino acid at position 91(E-G). The highest passage, CEL35 (GenBank: KY305949) produced 4nt bases changes in L1 loop at position 90(T-C), 133(A-T), 400(C-T) and 556(T-A) which lead to substitution in 3aa at position 44(D-V), 133(S-F) and 185(V-E) after serial passages in CEL cells. Analysis on fiber gene revealed several molecular changes involving tail, shaft and knob regions at position 1 to 66, 67 to 907 and 946 to 1094, respectively in nucleotide sequences. In deduced amino acid, those three regions were located at position 1 to 22, 23 to 303 and 316 to 364, respectively. Adaptation of UPM1137 at passage 5 (CEL5) (GenBank: KY305951) in CEL cells resulting four nt bases changes at position 31(T-C), 616(A-G), 652(G-A) and 963(A-G) with 3aa substitutions in deduced amino acid at position 11(S-P), 206(T-A) and 218(D-N). Following another five passaged in CEL cells, only 1nt base change was detected at position 971(A-T) resulting substitution of 1aa at location 324(Q-L) in CEL10 (GenBank: KY305952). The changes continually noticed in CEL15 (GenBank: KY305953) at 3 different position, 469(C-T), 483(C-T) and 732(A-T) in nt sequence along with 1aa change at position 157(P-S). Propagation of FAdV isolate at CEL20 (GenBank: KY305954) onwards induced 2nt bases substitutions at position 1050(A-C) and 1078(G-C) which resulting 1aa substitution at position 360(A-P). Another 2nt bases was substituted in CEL25 (GenBank: KY305955) at the region 839(A-G) and 1062(A-C) with 1aa change at position 280(N-S). Substitution of nt base at position 1062 were also consistent at CEL30 and CEL35. Additionally 2nt bases changes were detected in CEL30 (GenBank: KY305956) at position 295(A-G) and 680(T-C) which induced 2aa substitutions at position 99(T-A) and 227(L-S). Other 3nt bases was substituted at position 556(T-C), 821(T-A) and 1042(A-C) in CEL35 (GenBank: KY305957), which distinct from previous passage at CEL30. At deduced amino acid, 4aa changes were noticed at position 189(L-P) and 274(F-Y) in shaft region and in knob region at position 348(T-P) and 360(A-P). Phylogenetic tree analyses of 38 aligned aa based on hexon and fiber gene revealed classification of FAdV into five major groups from A to E species based on current ICTV nomenclature (Figs 4 and 5). The original FAdV isolate (E2) and the propagated FAdV isolates from every fifth passages were derived from species E and shared common ancestor with other FAdV-8 strains such as UPM08136, UPM08158, UPM04217, 764, HG, 430–06 and Australian FAdV vaccine. On the other hand, both duck and turkey adenovirus were not related to FAdV species which remained out group from generated phylogram and assigned with other genus of avian adenovirus group.
Fig 4

Phylogenetic tree of 198 amino acid residues based on L1 loop hexon gene shown the passaged FAdV isolates in CEL cells (shaded in dark gray) were classified under group E species (shaded in light gray).

Fig 5

Phylogenetic tree of amino acid residues based on fiber gene shown the passaged FAdV isolates in CEL cells (shaded in dark gray) was classified under group E species (shaded in light gray).

Pathogenicity and immunogenicity of attenuated FAdV, CEL35 isolate in SPF chickens

Neither the control nor the inoculated chickens with FAdV (CEL35) via oral or subcutaneous route exhibited any clinical signs, gross and histological lesions associated with FAdV infection throughout the trial (Fig 6(A), 6(B), 6(C) and 6(D)). The body weight of chickens in group A was significantly increased (p<0.05) from 70 ± 3g to 391 ± 26g at day 0 to 28pi, respectively. A similar pattern of body weight increment was recorded in groups B and C. However, there were no significant difference (p>0.05) on body weight in all groups of chickens throughout the trial. The FAdV antibody titre was not detected in group C throughout the trial. The antibody titre in group A was significantly (p<0.05) increased to 316 ± 118 and 163 ± 17 at days 14 and 28pi, respectively when compared to the control group. The antibody titre in group B also increased to 648 ± 188 and 324 ± 85 at days 14 and 28 pi respectively. There were no significant different (p>0.05) of antibody titre between route of inoculation either via oral or subcutaneous route.
Fig 6

SPF chicken at day 14pi showed normal gross and histological structure of liver in all group.

(a) Control group. (b) Group B of chicken inoculated with FAdV isolate subcutaneously. (c) Control group. (d) Group B of chicken inoculated with FAdV isolate subcutaneously. HE, Scale bar = 100μm.

SPF chicken at day 14pi showed normal gross and histological structure of liver in all group.

(a) Control group. (b) Group B of chicken inoculated with FAdV isolate subcutaneously. (c) Control group. (d) Group B of chicken inoculated with FAdV isolate subcutaneously. HE, Scale bar = 100μm.

Discussion

The study demonstrated that FAdV isolate (UPM1137) was successfully adapted and propagated for 35th consecutive passages in primary CEL cells with typical CPEs of FAdV infection. The virus caused basophilic intranuclear inclusion bodies with refractile, rounding, clumping and detachment of CEL cells. However, the CPE was not observed until day 3 pi at the first passage. Early CPE was recorded started from second to 19th passages within 24 to 48 hours pi and a slight delayed within 48 to 72 hours pi from CEL20 to CEL35. The virus titre was highest at passage 5 (107.6TCID50/mL) and remained high at the subsequence passages with the virus titre of 106.7TCID50/mL at passage 35. The development of CPE within 24 to 72 hours pi in CEL cells infected with FAdV reflects the sensitivity of this medium for FAdV replication even until passage 35 which is higher than previously reported [13, 14]. As compared to other cell lines such as Vero cells, its take more than 4 days pi for CPE to appear which is time consuming for propagation of the isolate [16]. These sensitive medium resembled in vivo conditions since nucleus of liver cells are the viral tropism for FAdV replication. Nevertheless, liver comprising high level expression of coxsackievirus-adenovirus receptor (CAR) and integrin receptor for adenovirus fiber binding to trigger infection [24, 25]. As a result, CPE formation with massive destruction of monolayer culture within early period of time was observed in this study as indicator of viral replication. With the ability of FAdV isolate to replicate and propagate at high passage level and produce high virus titre, it was demonstrated that CEL cells is a suitable medium for propagation and attenuation of the virus. The present study revealed substitution of nucleotide base at position 90 from cytosine to thymine in L1 loop of hexon gene was detected in FAdV passaged isolate in CEL cells. It seems that these changes are crucial for the isolate to remain viable and growth in the CEL cells for 35 passages since the changes was not seen in original isolate (E2). Additionally, in fiber gene, substitution of amino acid at position 360 from alanine (A) to proline (P) resulted delaying in CPE formation within 48 to 72 hours pi in passaged isolate from CEL20 onwards. As compared to early 15 passages, CPE produced within 24 to 48 hours without interference at this amino acid region. The current finding was proved that serial passages of FAdV in CEL cells exhibit marker gene for adaptation and exposed molecular changes at the area encoded for virus infectivity. Molecular changes were significant at highest passage (CEL35) in both L1 loop and knob region in hexon and fiber gene, respectively. Substitutions of deduced amino acid 44(D-V), 133(S-F) and 185(V-E) in L1 loop region along with amino acid 348(T-P) in knob of fiber gene in CEL35 are indicator of marker for the virus attenuation in CEL cells since these changes were not detected in other early passages. Based on present findings, modification of knob region reduced binding affinity towards host cells receptor which affect virus infectivity in CEL and SPF chickens as compared to other part of fiber gene [10, 26, 27]. It shown that low amino acid identities were determined in knob region between high and low virulent FAdV isolates as reported in previous study and corroborated with current findings [17]. Additionally, mutation in L1 loop of hexon gene also resulting virus attenuation in embryonated chicken eggs [12]. Several changes occurs in L1 loop at CEL20 to CEL35 suggested that intervention at this region in hexon gene structure by serial passages in CEL cells might reduce virus capability to replicate in the cells with delayed in period of CPE formation. Propagation of FAdV isolate at passages CEL5, CEL10 and CEL15, induce minimal number of nucleotide and amino acid changes in hexon and fiber genes at variable region. Interestingly, as increased passage level, there are increased in number of changes ranging from 2 to 5nt bases in hexon and 2 to 6nt bases in fiber gene from CEL20 onwards. It was demonstrated that molecular changes in all passaged isolates were not interfere antigenicity of FAdV. Based on FAdV classification, the passaged isolate at highest passage, CEL35 remained in the group E species under serotype 8b in hexon and fiber gene. It was confirmed that the CEL35 isolate was attenuated and non-pathogenic in SPF chickens. Neither mortality nor gross and histological lesions were observed in all chickens throughout the trial. A similar finding was observed in previous studies following inoculation of passaged isolate with high molecular changes [12, 28]. It was shown that substitution of amino acids in CEL35 isolate at position 44, 133 and 185 in L1 loop of hexon gene and at position 348 in knob of fiber gene affect virus infectivity in SPF chickens and was identified as marker gene for attenuation. The CEL35 isolate is immunogenic and able to induce antibody titre at days 14 and 28pi when the virus was inoculated either via subcutaneous or oral route in SPF chickens.

Conclusion

It was concluded that consecutive passages of FAdV serotype 8b isolate in primary CEL cells can induce viral attenuation with molecular changes in major capsid proteins and affect virus infectivity in cell culture and SPF chickens.

GenBank databases for Fowl Adenovirus sequence references.

(DOCX) Click here for additional data file. 23 Sep 2019 PONE-D-19-20512 MOLECULAR CHARACTERIZATION OF FOWL ADENOVIRUS ISOLATE OF MALAYSIA ATTENUATED IN CHICKEN EMBRYO LIVER CELLS AND IT’S PATHOGENICITY AND IMMUNOGENICITY IN SPECIFIC PATHOGEN FREE CHICKENS PLOS ONE Dear Prof Bejo, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== I am delighted to accept your manuscript for publication in PLOS ONE with minor revisions, also, my apologies for the delay. It took much longer than I anticipated to recruit reviewers for your manuscript. I agree with the reviewer recommendation to shorten the title, but the decision is solely yours and will not effect the decision to publish your findings. ============================== We would appreciate receiving your revised manuscript by Nov 07 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript: A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Negin P. Martin, Ph.D. Academic Editor PLOS ONE Journal requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels. In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions. Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Fowl adenovirus (FAdV) is the causative agent of inclusion body hepatitis (IBH) in chickens with significant economic losses. Authors conducted the study to attenuate and determine the molecular characteristic of FAdV isolate (UPM1137) of Malaysia passages in primary chicken embryo liver (CEL) cells. The cytopathic effect (CPE) was recorded and the present of the virus was detected by polymerase chain reaction (PCR). Authors also have detected intranuclear inclusion bodies in primary CEL cells by hematoxylin and eosin staining. The next step of conducted study the authors evaluated virus titration and DNA extraction, PCR and cloning. Nucleotide and amino acid changes were determined and a phylogenetic tree was constructed. The pathogenicity and immunogenicity of the virus at passage 35 (CEL35) with virus titre of 10 6.7TCID50/mL was determined in day old specific pathogen free (SPF) chicks via oral or subcutaneous route of inoculation.The study demonstrated that the FAdV isolate was successfully propagated and attenuated in CEL cells up to 35th consecutive passages (CEL35) with delayed of CPE formation within 48 to 72 post inoculation (pi) from CEL20 onwards. The virus caused typical CPE with basophilic intranuclear inclusion bodies, refractile and clumping of cells. Statistical analysis have been conducted and independent T-test was performed. The virus was classify to serotype 8b with substitution of amino acid at position 44, 133 and 185 in L1 loop of hexon gene and in knob of fiber gene at position 348 and 360 at CEL35. It is non-pathogenic, but immunogenic in SPF chickens. It was concluded that the FAdV isolate was successfully attenuated in CEL cells with molecular changes in major capsid proteins which affect it’s infectivity in cell culture and SPF chickens. The manuscript is well written and has an impact in front of adenovirus molecular investigation. I am for the publication this manuscript in PLOS one Journal. Reviewer #2: 1- The manuscript title "MOLECULAR CHARACTERIZATION OF FOWL ADENOVIRUS ISOLATE OF MALAYSIA ATTENUATED IN CHICKEN EMBRYO LIVER CELLS AND IT’S PATHOGENICITY AND IMMUNOGENICITY IN SPECIFIC PATHOGEN FREE CHICKENS" is too long it may be changed and shortened? see one example below. "MOLECULAR CHARACTERIZATION OF A MALAYSIAN FOWL ADENOVIRUS ISOLATE ATTENUATED IN CHICKEN EMBRYO LIVER CELLS" 2- You should also describe about SPF chickens, either they were SPF broilers or layers? ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Niczyporuk Jowita Samanta Reviewer #2: Yes: Dr. M. Salah-ud-Din Shah [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. 9 Nov 2019 1) The manuscript title "MOLECULAR CHARACTERIZATION OF FOWL ADENOVIRUS ISOLATE OF MALAYSIA ATTENUATED IN CHICKEN EMBRYO LIVER CELLS AND IT’S PATHOGENICITY AND IMMUNOGENICITY IN SPECIFIC PATHOGEN FREE CHICKENS" is too long it may be changed and shortened? see one example below. "MOLECULAR CHARACTERIZATION OF A MALAYSIAN FOWL ADENOVIRUS ISOLATE ATTENUATED IN CHICKEN EMBRYO LIVER CELLS" Answer: The study involved with attenuation of Fowl adenovirus in chicken embryo liver cells (CEL) and characterized molecularly the virus characteristic resulted from attenuation of virus in CEL. In addition to molecular characterization, the study also determine the pathogenicity and immunogenicity of the virus in chickens. Thus, the original title reflect more clearly on the study and contents of the manuscript. It is advisable to remove the specific pathogen free (SPF) to shorten the title. The CEL was prepared form liver of SPF chicken embryo as well as the pathogenicity and immunogenicity were conducted in SPF chickens. SPF was not mentioned in CEL. Thus, it justify to remove SPF for the chickens. New title: "MOLECULAR CHARACTERIZATION OF FOWL ADENOVIRUS ISOLATE OF MALAYSIA ATTENUATED IN CHICKEN EMBRYO LIVER CELLS AND IT’S PATHOGENICITY AND IMMUNOGENICITY IN CHICKENS" 2) You should also describe about SPF chickens, either they were SPF broilers or layers? Answer: The SPF chickens used in the study was from SPF White Leghorns layer chickens. It is included in the revised manuscript. Submitted filename: Response to Reviewers.docx Click here for additional data file. 14 Nov 2019 MOLECULAR CHARACTERIZATION OF FOWL ADENOVIRUS ISOLATE OF MALAYSIA ATTENUATED IN CHICKEN EMBRYO LIVER CELLS AND IT`S PATHOGENICITY AND IMMUNOGENICITY IN CHICKENS PONE-D-19-20512R1 Dear Dr. Bejo, We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements. Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication. Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. With kind regards, Negin P. Martin, Ph.D. Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: 19 Dec 2019 PONE-D-19-20512R1 Molecular Characterization of Fowl Adenovirus Isolate of Malaysia Attenuated in Chicken Embryo Liver Cells and It’s Pathogenicity and Immunogenicity in Chickens Dear Dr. Bejo: I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. For any other questions or concerns, please email plosone@plos.org. Thank you for submitting your work to PLOS ONE. With kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Negin P. Martin Academic Editor PLOS ONE
  18 in total

1.  Preparation and evaluation of chicken embryo-adapted fowl adenovirus serotype 4 vaccine in broiler chickens.

Authors:  Muhammad Khalid Mansoor; Iftikhar Hussain; Muhammad Arshad; Ghulam Muhammad
Journal:  Trop Anim Health Prod       Date:  2010-09-28       Impact factor: 1.559

2.  Comparison of fiber gene sequences of inclusion body hepatitis (IBH) and non-IBH strains of serotype 8 and 11 fowl adenoviruses.

Authors:  Helena Grgić; Peter J Krell; Eva Nagy
Journal:  Virus Genes       Date:  2013-10-20       Impact factor: 2.332

3.  Inclusion body hepatitis as a primary disease in broilers in Saskatchewan, Canada.

Authors:  Susantha Gomis; A Robert Goodhope; A Davor Ojkic; Philip Willson
Journal:  Avian Dis       Date:  2006-12       Impact factor: 1.577

4.  Pathogenicity and complete genome sequence of a fowl adenovirus serotype 8 isolate.

Authors:  Helena Grgić; Dan-Hui Yang; Eva Nagy
Journal:  Virus Res       Date:  2011-01-14       Impact factor: 3.303

5.  Defining CAR as a cellular receptor for the avian adenovirus CELO using a genetic analysis of the two viral fibre proteins.

Authors:  Poi Kiang Tan; Anne-Isabelle Michou; Jeffrey M Bergelson; Matt Cotten
Journal:  J Gen Virol       Date:  2001-06       Impact factor: 3.891

6.  Fowl adenovirus (FAdV) serotype 4 causes depletion of B and T cells in lymphoid organs in specific pathogen-free chickens following experimental infection.

Authors:  Esther Schonewille; Amarjit Singh; Thomas W Göbel; Wilhelm Gerner; Armin Saalmüller; Michael Hess
Journal:  Vet Immunol Immunopathol       Date:  2007-10-02       Impact factor: 2.046

7.  Genetic characterization, pathogenicity, and protection studies with an avian adenovirus isolate associated with inclusion body hepatitis.

Authors:  I R Alvarado; P Villegas; J El-Attrache; E Jensen; G Rosales; F Perozo; L B Purvis
Journal:  Avian Dis       Date:  2007-03       Impact factor: 1.577

8.  Hexon based PCRs combined with restriction enzyme analysis for rapid detection and differentiation of fowl adenoviruses and egg drop syndrome virus.

Authors:  R Raue; M Hess
Journal:  J Virol Methods       Date:  1998-08       Impact factor: 2.014

9.  Studies on the development of avian adenoviruses in cell cultures.

Authors:  B M Adair
Journal:  Avian Pathol       Date:  1978-10       Impact factor: 3.378

10.  Hexon and fiber gene changes in an attenuated fowl adenovirus isolate from Malaysia in embryonated chicken eggs and its infectivity in chickens.

Authors:  Norfitriah M Sohaimi; Mohd H Bejo; Abdul R Omar; Aini Ideris; Nurulfiza M Isa
Journal:  J Vet Sci       Date:  2018-11-30       Impact factor: 1.672

View more
  5 in total

1.  Transcriptome Analysis of Genes Responding to Infection of Leghorn Male Hepatocellular Cells With Fowl Adenovirus Serotype 4.

Authors:  Xueping P Wang; Bo Wen; Xiao J Zhang; Lei Ma; Xiu L Liang; Ming L Zhang
Journal:  Front Vet Sci       Date:  2022-06-14

Review 2.  A recent perspective on fiber and hexon genes proteins analyses of fowl adenovirus toward virus infectivity-A review.

Authors:  Norfitriah Mohamed Sohaimi; Mohd Hair-Bejo
Journal:  Open Vet J       Date:  2021-10-19

Review 3.  Historical Investigation of Fowl Adenovirus Outbreaks in South Korea from 2007 to 2021: A Comprehensive Review.

Authors:  Jongseo Mo
Journal:  Viruses       Date:  2021-11-10       Impact factor: 5.048

4.  High Phenotypic Variation between an In Vitro-Passaged Fowl Adenovirus Serotype 1 (FAdV-1) and Its Virulent Progenitor Strain despite Almost Complete Sequence Identity of the Whole Genomes.

Authors:  Beatrice Grafl; Anna Schachner; Michael Hess
Journal:  Viruses       Date:  2022-02-09       Impact factor: 5.048

5.  Epidemiological and molecular analysis of circulating fowl adenoviruses and emerging of serotypes 1, 3, and 8b in Egypt.

Authors:  Amany Adel; Ahmed Abd Elhalem Mohamed; Mahmoud Samir; Naglaa M Hagag; Ahmed Erfan; Mahmoud Said; Abd El Satar Arafa; Wafaa M M Hassan; Mohamed E El Zowalaty; Momtaz A Shahien
Journal:  Heliyon       Date:  2021-11-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.